MMP-2 Induced Vein Relaxation via Inhibition of [Ca2+]e-Dependent Mechanisms of Venous Smooth Muscle Contraction. Role of RGD Peptides

Journal of Surgical Research

Volumn 159, Issue 2, 2010, Pages 755-764

  Raffetto, Joseph D ^a,c   Barros, Yaskara V R ^a   Wells, Amanda K ^a   Khalil, Raouf A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

calcium; extracellular matrix; inferior vena cave; matrix metalloproteinase; varicose veins; vascular smooth muscle

Indexed keywords

ANGIOTENSIN II; ARGININE; ASPARTIC ACID; CALCIUM ION; DILTIAZEM; GELATINASE A; GLYCINE; INTEGRIN RECEPTOR; PEPTIDE; PHENYLALANINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; HISTOLOGY; INFERIOR CAVA VEIN; MALE; MEMBRANE CHANNEL; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MUSCLE CONTRACTION; OLIGOPEPTIDES; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; VARICOSE VEINS; VASOCONSTRICTION; VASODILATION; VENA CAVA, INFERIOR;

EID: 77949486220     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.09.022     Document Type: Article

References (51)

1. Goldman M.P., and Fronek A. Anatomy and pathophysiology of varicose veins. J Dermatol Surg Oncol 15 (1989) 138
2. Woosside K.J., Hu M., Burke A., et al. Morphologic characteristics of varicose veins: Possible role of metalloproteinases. J Vasc Surg 38 (2003) 162
3. Gandhi R.H., Irizarry E., Nackman G.B., et al. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 18 (1993) 814
4. Carpentier P.H., Maricq H.R., Biro C., et al. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: A population-based study in France. J Vasc Surg 40 (2004) 650
5. Ruckley C.V., Evans C.J., Allan P.L., et al. Chronic venous insufficiency: Clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. J Vasc Surg 36 (2002) 520
6. Gillespie D.L., Patel A., Fileta B., et al. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res 106 (2002) 233
7. Pascarella L., Penn A., and Schmid-Schonbein G.W. Venous hypertension and the inflammatory cascade: Major manifestations and trigger mechanisms. Angiology 56 Suppl 1 (2005) S3
8. Kowalewski R., Sobolewski K., Wolanska M., et al. Matrix metalloproteinases in the vein wall. Int Angiol 23 (2004) 164
9. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92 (2003) 827
10. Raffetto J.D., and Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75 (2008) 346
11. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008 (in press).
12. Raffetto J.D., Ross R.L., and Khalil R.A. Matrix metalloproteinase-2 induced venous dilation via hyperpolarization and activation of K+ channels: Relevance to varicose vein formation. J Vasc Surg 45 (2007) 373
13. Chew D.K.W., Conte M.S., and Khalil R.A. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 40 (2004) 1001
14. Martinez-Lemus L.A., Wu X., Wilson E., et al. Integrins as unique receptors for vascular control. J Vasc Res 40 (2003) 211
15. Davis M.J., Wu X., Nurkiewicz T.R., et al. Integrins and mechanotransduction of the vascular myogenic response. Am J Physiol Heart Circ Physiol 280 (2001) H1427
16. Takada Y., Ye X., and Simon S. The integrins. Genome Biol 8 (2007) 215
17. Kerr J.S., Wexler R.S., Mousa S.A., et al. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 19 (1999) 959
18. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491
19. Ries C., Pitsch T., Mentele R., et al. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukemic cells: (Auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem J 405 (2007) 547
20. Maquoi E., Sounni N.E., Devy L., et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 10 (2004) 4038
21. Kruse M.N., Becker C., Lottaz D., et al. Human meprin α and β homo-oligomers: Cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J 378 (2004) 383
22. i induced by RGD-containing peptide. Am J Physiol 272 (1997) H2065
23. Hein T.W., Platts S.H., Waitkus-Edwards K.R., et al. Integrin-binding peptides containing RGD produce coronary arteriolar dilation via cyclooxygenase activation. Am J Physiol Heart Circ Physiol 281 (2001) H2378
24. Meng Q., Malinovskii V., Huang W., et al. Residue 2 of TIMP-1 is a major determinant of affinity and specificity from matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. J Biol Chem 274 (1999) 10184
25. Liu Y.E., Wang M., Greene J., et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 272 (1997) 20479
26. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90 (2002) 251
27. Khalil R.A., and van Breemen C. Sustained contraction of vascular smooth muscle: Calcium influx or C-kinase activation?. J Pharmacol Exp Ther 244 (1988) 537
28. Pattni K., and Banting G. Ins (1,4,5)P3 metabolism and the family of IP3-3Kinases. Cell Signal 16 (2004) 643
29. Szlufcik K., Missiaen L., Parys J.B., et al. Uncoupled IP3 receptor can function as a Ca2+-leak channel: Cell biological and pathological consequences. Biol Cell 98 (2006) 1
30. Mikoshiba K. IP3 receptor/Ca2+ channel: From discovery to new signaling concepts. J Neurochem 102 (2007) 1426
31. Falcinelli E., Guglielmini G., Torti M., et al. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost 3 (2005) 2526
32. Triggle D.J. Calcium channel antagonists: Clinical uses-past, present, and future. Biochem Pharmacol 74 (2007) 1
33. Romero M., Sánchez I., and Pujol M.D. New advances in the field of calcium channel antagonists: Cardiovascular effects and structure-activity relationships. Curr Med Chem Cardiovasc Hematol Agents 1 (2003) 113
34. Triggle D.J. L-type calcium channels. Curr Pharm Des 12 (2006) 443
35. Khalil R.A., and van Breemen C. Intracellular free calcium concentration/force relationship in rabbit inferior vena cava activated by norepinephrine and high K+. Pflüger's Arch 416 (1990) 727
36. Mogford J.E., Davis G.E., Platts S.H., et al. Vascular smooth muscle α v β 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 79 (1996) 821
37. Wu X., Mogford J.E., Platts S.H., et al. Modulation of calcium current in arteriolar smooth muscle by α v β3 and α5 beta1 integrin ligands. J Cell Biol 143 (1998) 241
38. Lipke D.W., Soltis E.E., Fiscus R.R., et al. RGD-containing peptides induce endothelium-dependent and independent vasorelaxations of rat aortic rings. Regul Pept 63 (1996) 23
39. Srivatsa S.S., Fitzpatrick L.A., Tsao P.W., et al. Selective α v β 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin α v β 3 and osteopontin expression during neointima formation. Cardiovasc Res 36 (1997) 408
40. Platts S.H., Mogford J.E., Davis M.J., et al. Role of K+ channels in arteriolar vasodilation mediated by integrin interaction with RGD-containing peptide. Am J Physiol 275 4 Pt 2 (1998) H1449
41. Bakker E.N., Balt J.C., Pfaffendorf M., et al. Vasomotor effects of arg-gly-asp (RGD) peptides are limited and not related to endothelium-derived hyperpolarizing factor-mediated relaxation in rat mesenteric arteries. Clin Exp Pharmacol Physiol 28 (2001) 873
42. Goligorsky M.S., and DiBona G.F. Pathogenetic role of Arg-Gly-Asp-recognizing integrins in acute renal failure off. Proc Natl Acad Sci USA 90 (1993) 5700
43. Yip K.P., and Marsh D.J. An Arg-Gly-Asp peptide stimulates constriction in rat afferent arteriole. Am J Physiol 273 5 Pt 2 (1997) F768
44. Chan W.L., Holstein-Rathlou N.H., and Yip K.P. Integrin mobilizes intracellular Ca(2+) in renal vascular smooth muscle cells. Am J Physiol Cell Physiol 280 (2001) C593
45. Martinez-Lemus L.A., Crow T., Davis M.J., et al. α v β3- and α 5 β1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol Heart Circ Physiol 289 (2005) H322
46. Macfarlane S.R., Seatter M.J., Kanke T., et al. Proteinase-activated receptors. Pharmacol Rev 53 (2001) 245
47. Fiore E., Fusco C., Romero P., et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21 (2002) 5213
48. Marutsuka K., Hatakeyama K., Sato Y., et al. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VII complex. Thromb Res 107 (2002) 271
49. Hamilton J.R., Nguyen P.B., and Cocks T.M. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res 82 (1998) 1306
50. Takase S., Pascarella L., Bergan J.J., et al. Hypertension-induced venous valve remodeling. J Vasc Surg 39 (2004) 1329
51. Pascarella L., Schmid-Schonbein G.W., and Bergan J.J. An animal model of venous hypertension: The role of inflammation in venous valve failure. J Vasc Surg 41 (2005) 303